(firstQuint)Lorcaserin for Preventing Weight Gain Among Smokers.

 This will be an open label clinical trial with all subjects receiving both lorcaserin and varenicline.

 The investigators will obtain preliminary data on the efficacy of lorcaserin (10 mg twice daily) for 12 weeks in 20 adult weight-concerned cigarette smokers with a BMI of 27 to 40 simultaneously receiving 12 weeks of open-label varenicline and a behavioral intervention to assist with stopping smoking.

 Secondary aims will be weight, waist circumference, and smoking cessation.

.

 Lorcaserin for Preventing Weight Gain Among Smokers@highlight

This will be an open label clinical trial with all subjects receiving both lorcaserin and varenicline with a primary aim of reducing post cessation weight gain.

